1. PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model

2. CONFERENCE OF MONTREAL 20142 Information of December 31 st 2013 OUR GROUP SANOFI AT A GLANCE We are a global healthcare company engaged in the research, development, manufacturing and marketing of healthcare solutions. present in more than 100 countries more than 110 000 employees A comprehensive offer of pharmaceuticals, vaccines and innovative therapeutic solutions 112 Industrial sites in 41 countries R&D A major biopharmacy player 45% of revenues generated by biologics 80% of development projects are biologics €33 bn * In sales in 2013 * €32,951 M

3. Multiple Sclerosis Diabetes Oncology Rare Diseases Cardio-Metabolic Diseases Immunology Vaccines Animal Health CONFERENCE OF MONTREAL 20143 We act as one to discover and develop therapies that prevent, treat and cure disease. 9 projects and vaccines in clinical development* high potential projects in late stage development* 49 SANOFI R&D ACCELERATE INNOVATION FOR PATIENTS Our main areas of research include: *Information provided as of February 6 th, 2014

4. CONFERENCE OF MONTREAL 20144 OUR RESPONSIBILITY CHANGE THE R&D INNOVATION MODEL The classic INNOVATION model Belief that advances in basic sciences can be easily translated to human disease A linear process from discovery to development to market with little interactions throughout the innovation cycle Focus on novel (but not necessarily validated) targets in humans A strategy of “Many Shots on Goal” A non-linear process that takes into account provider, purchaser and user metrics including pipeline activity, clinical success, regulatory approval, patient access, satisfaction of unmet need and overall value to society A greater understanding of human disease Open innovation and partnership The new INNOVATION model Raising the batting average!

5. CONFERENCE OF MONTREAL 20145 OUR PRESIDENT OF R&D PATIENTS ARE THE MISSING LINK

6. CONFERENCE OF MONTREAL 20146 Increasing public awareness & improving clinical trial education MAKING CLINICAL TRIALS PATIENT FRIENDLY SO WHAT ARE WE DOING ABOUT IT? What do patients know about clinical research? How do they get their facts? How do they know if a study exists? Do they ever hear the results? Bringing patients within the project team e.g. Diabetes Patient Advisors input into study designs, innovation & outreach strategies Innovating to ease patient experience e-informed consent e-technology (e.g. telemetry) Point of care technologies (e.g. Dried Blood Spots)

7. CONFERENCE OF MONTREAL 20147 SO WHAT ARE WE DOING ABOUT IT? BEFORE AND BEYOND CLINICAL TRIALS Opportunities exists from target to use Target identification Path to proof of concept Effective value Access Partner in Patient Health (PiPH) initiative EU-NA PiPH Council Collaborate | Innovate Challenge Newly created position of Chief Patient Officer

8. CONFERENCE OF MONTREAL 20148 OUR “RAISON D’ETRE” ACCELERATE INNOVATION FOR PATIENTS